Schizophrenia Research Trends

More documents

Recommendations

Info

110Stephen I. Deutsch, John Mastropaolo and Barbara L. SchwartzREFERENCESAkbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, SandmanCA, Bunney WE Jr., Jones EG. Selective alterations in gene expression for NMDAreceptor subunits in prefrontal cortex of schizophrenics. Journal of Neuroscience 1996;16: 19-30.Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Increased GABA receptorbinding in superficial layers of cingulated cortex in schizophrenics. Journal ofNeuroscience. 1992; 12: 924-929.Billingslea EN, Mastropaolo J, Rosse RB, Bellack AS, Deutsch SI. Interaction of stress andstrain on glutamatergic neurotransmission: Relevance to schizophrenia. PharmacologyBiochemistry and Behavior 2003; 74(2): 351-356.Bonhaus SW, Burge BC, McNamara JO. Biochemical evidence that glycine allostericallyregulates an NMDA receptor-coupled ion channel. Eur J Pharmacol 1987; 142: 489-490.Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Review ofPsychiatry 1996; 3: 241-253.Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A “glutamatergichypothesis” of schizophrenia: rationale for pharmacotherapy with glycine. ClinicalNeuropharmacology 1989; 12: 1-13.Deutsch SI, Deutsch LH, Weizman R. Nonketotic hyperglycinemia: a paradigm for theapplication of neuroscience to the understanding and treatment of a developmentaldisorder. In: Deutsch SI, Weizman A, Weizman R, eds. Application of basicneuroscience to child psychiatry. New York: Plenum Publishing Corporation, 1990, pp.165-180.Deutsch SI, Hitri A: Measurement of an explosive behavior in the mouse induced by MK-801, A PCP analogue. Clinical Neuropharmacology 1993; 16(3): 251-257.Deutsch SI, Park CH, Lukacs LG, Morn C, Koetzner L, Mastropaolo J. MK-801 alters theGABA A receptor complex and potentiates flurazepam's antiseizure efficacy.Pharmacology Biochemistry and Behavior 1995; 51(4): 909-915.Deutsch SI, Rosse RB, Paul SM, Tomasino V, Koetzner BA, Morn CB, Mastropaolo J. 7-Nitroindazole and metylene blue, inhibitors of neuronal nitric oxide synthase and nostimulatedguanylate cyclase, block MK-801 elicited behaviors in mice.Neuropsychopharmacology 1996; 15: 37-43.Deutsch SI, Rosse RB, Riggs RL, Koetzner L, Mastropaolo J. The competitive NMDAantagonist CPP blocks MK-801-elicited popping behavior in mice.Neuropsychopharmacology 1996; 15:329-331.Deutsch SI, Rosse RB, Paul SM, Riggs RL, Mastropaolo J. Inbred mouse strains differ insensitivity to popping elicited by MK-801. Pharmacology Biochemistry and Behavior;57(1/2): 315-317.Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg P, and Fearing K.Methylene blue adjuvant therapy of schizophrenia. Clinical Neuropharmacology 1997;20(4): 357-363.
NMDA Receptor Hypofunction in <strong>Schizophrenia</strong>: From Mouse to Man 111Deutsch SI, Mastropaolo J, Riggs RL, and Rosse RB. The antiseizure efficacies of MK-801,phencyclidine, ketamine and memantine are altered selectively by stress. PharmacologyBiochemistry and Behavior 1997; 58(3): 709-712.Deutsch SI, Rosse RB, and Mastropaolo J. Behavioral approaches to the functionalassessment of NMDA-mediated neural transmission in intact mice. ClinicalNeuropharmacology 1997; 20(5):375-384.Deutsch SI, Rosse RB, Mastropaolo J. Current status of NMDA antagonist interventions inthe treatment of nonketotic hyperglycinemia. Clinical Neuropharmacology 1998; 21(2):71-79.Deutsch SI, Mastropaolo J, Powell DG, Rosse RB, Bachus SE. Inbred mouse strains differ intheir sensitivity to an antiseizure effect of MK-801. Clinical Neuropharmacology 1998;21(4): 255-257.Deutsch SI, Mastropaolo J, Rosse RB. Neurodevelopmental consequences of early exposureto phencyclidine and related drugs. Clinical Neuropharmacology 1998; 21(6): 320-332.Deutsch SI, Rosse RB, Schwartz BL, Powell DG, and Mastropaolo J. Stress and a glycinergicintervention interact in the modulation of MK-801-elicited mouse popping behavior.Pharmacology Biochemistry and Behavior 1999; 62(2): 395-398.Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis ofschizophrenia: therapeutic implications. Clinical Neuropharmacology 2001; 24: 43-49.Deutsch SI, Rosse RB, Billingslea EB, Bellack AS, Mastropaolo J. Topiramate antagonizesMK-801 in an animal model of schizophrenia. European Journal of Pharmacology 2002;449(1): 121-125.Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvanttopiramate administration: A pharmacological strategy for addressing NMDA receptor orhypofunction in schizophrenia. Clinical Neuropharmacology 2003; 26(4): 199-206.Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. Modulation of MK-801–elicited mouse popping behavior by galantamine is complex and dose-dependent. LifeSciences 2003; 73(18): 2355-2361.Deutsch SI, Rosse RB, Schwartz BL, Weizman A, Chilton M, Arnold DS, Mastropaolo J.Therapeutic implications of selective alpha7 nicotinic receptor abnormality inschizophrenia. Israel Journal of Psychiatry 2005; 42(1): 33-44.Drapalski AL, Rosse RB, Peebles RP, Schwartz BL, Marvel CL, Deutsch SI. Topiramateimproves deficit symptoms in a patient with schizophrenia when added to a stableregimen of antipsychotic medication. Clinical Neuropsychopharmacology 2001; 24: 290-294.Fagg GE. Phencyclidine and related drugs bind to the activated N-methyl-D-aspartatereceptor-channel complex in rat brain membranes. Neurosci Lett 1987; 76: 221-227.Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders.Progress in Brain <strong>Research</strong> 1998; 116:421-437.Foster AC, Wong EHF. The novel anticonvulsant MK-801 binds to the activated state of theN-methyl-D-aspartate receptor in rat brain. Br J Pharmacol 1987; 91: 403-409.Freed WJ, Crump S, Jeste DV. Genetic effects on PCP-induced stimulation in recombinantinbred strains of mice. Pharmacol Biochem Behav 1984; 21(1): 159-162.
Page 3:
SCHIZOPHRENIA RESEARCH TRENDS
Page 6 and 7:
Copyright © 2008 by Nova Science P
Page 9 and 10:
PREFACESchizophrenia is a chronic,
Page 11 and 12:
Prefaceixdisorder with symptoms man
Page 13 and 14:
In: Schizophrenia Research Trends I
Page 15 and 16:
Body Image Deviation in Chronic Sch
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65:
Page 68 and 69:
56Guy SandnerSubsets of the Disease
Page 72 and 73: 60Guy Sandnerlinked to the ongoing
Page 74 and 75: 62Guy Sandnercorrelated with its pr
Page 76 and 77: 64Guy Sandner(general thought disor
Page 78 and 79: 66Guy Sandneramnesic patients. Thes
Page 80 and 81: 68Guy Sandneras soon as their early
Page 82 and 83: 70Guy Sandnerrole games [106, 142].
Page 84 and 85: 72Guy Sandnerand the cause of the d
Page 86 and 87: 74Guy SandnerA third explanation pl
Page 88 and 89: 76Guy Sandner2. Rats with neonatal
Page 90 and 91: 78Guy SandnerBOX 1DiagnosisPositive
Page 92 and 93: 80Guy SandnerBOX 2Cognitive Science
Page 94 and 95: 82Guy SandnerREFERENCES[1] Alberts
Page 96 and 97: 84Guy Sandner[36] Corcoran R, Merce
Page 98 and 99: 86Guy Sandner[71] Frank N, Farrer C
Page 100 and 101: 88Guy Sandner[103] Jeon YW, Polich
Page 102 and 103: 90Guy Sandner[136] McGurk SR, Muese
Page 104 and 105: 92Guy Sandner[168] Sato Y, Yabe H,
Page 107 and 108: In: Schizophrenia Research Trends I
Page 109 and 110: NMDA Receptor Hypofunction in Schiz
Page 121: NMDA Receptor Hypofunction in Schiz
Page 129 and 130: Evolution and Schizophrenia 117In 1
Page 131 and 132: Evolution and Schizophrenia 119Over
Page 133 and 134: Evolution and Schizophrenia 121psyc
Page 135 and 136: Evolution and Schizophrenia 123deri
Page 137 and 138: Evolution and Schizophrenia 125indi
Page 139 and 140: Evolution and Schizophrenia 127pred
Page 141 and 142: Evolution and Schizophrenia 129one
Page 143 and 144: Evolution and Schizophrenia 131REFE
Page 145 and 146: Evolution and Schizophrenia 133[41]
Page 147 and 148: Evolution and Schizophrenia 135[80]
Page 151 and 152: Latent Inhibition and Learned Irrel
Page 173:
Latent Inhibition and Learned Irrel
Page 176 and 177:
164M. Nieznański, A. Chojnowska, W
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
184Special Book Bibliography on Sch
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 261 and 262:
INDEXAabdomen, 38abnormal, 132abuse
Page 263 and 264:
Index 251BMA, 216body, vii, viii, 1
Page 265 and 266:
Index 253CRR, 90CTA, 139, 140, 143,
Page 267 and 268:
Index 255eyes, 6, 24, 25, 50, 52, 6
Page 269 and 270:
Index 257inhibition, ix, x, 60, 64,
Page 271 and 272:
Index 259metabolism, 97, 103, 105,
Page 273 and 274:
Index 261personal accounts, 123pers
Page 275 and 276:
Index 263risk, 23, 26, 30, 39, 48,
Page 277 and 278:
Index 265Ttactile stimuli, 85Taiwan
show all

Schizophrenia Research Trends

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?